statistiche ricercatore

Continente	#
EU - Europa	505
NA - Nord America	478
AS - Asia	324
SA - Sud America	94
Continente sconosciuto - Info sul continente non disponibili	22
AF - Africa	12
OC - Oceania	1
Totale	1.436

Nazione	#
US - Stati Uniti d'America	460
RU - Federazione Russa	341
SG - Singapore	156
BR - Brasile	77
CN - Cina	62
HK - Hong Kong	35
IE - Irlanda	35
IT - Italia	27
SE - Svezia	27
VN - Vietnam	24
GB - Regno Unito	14
DE - Germania	13
FR - Francia	11
CA - Canada	10
FI - Finlandia	9
BD - Bangladesh	8
IN - India	8
NL - Olanda	7
PK - Pakistan	7
AR - Argentina	5
PL - Polonia	5
ZA - Sudafrica	5
AL - Albania	3
AT - Austria	3
BE - Belgio	3
BO - Bolivia	3
DZ - Algeria	3
KG - Kirghizistan	3
MX - Messico	3
PE - Perù	3
PH - Filippine	3
TR - Turchia	3
CZ - Repubblica Ceca	2
JO - Giordania	2
MA - Marocco	2
MY - Malesia	2
PY - Paraguay	2
VE - Venezuela	2
AE - Emirati Arabi Uniti	1
CL - Cile	1
CR - Costa Rica	1
CY - Cipro	1
EC - Ecuador	1
EG - Egitto	1
ES - Italia	1
ET - Etiopia	1
GT - Guatemala	1
ID - Indonesia	1
IL - Israele	1
IQ - Iraq	1
IR - Iran	1
JM - Giamaica	1
JP - Giappone	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LC - Santa Lucia	1
LT - Lituania	1
LU - Lussemburgo	1
NP - Nepal	1
NZ - Nuova Zelanda	1
PA - Panama	1
RO - Romania	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
Totale	1.414

Nome	#
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors	200
Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis	163
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound	158
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study	155
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data	104
The effect of drugs used in rheumatology for treating SARS-CoV2 infection	98
Concerns about the safety of anti-TNF agents when treating rheumatic diseases	97
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases	95
Toxicological considerations in the treatment of axial spondylo-arthritis	79
The rheumatology drugs for COVID-19 management: Which and when?	77
Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications	72
Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?	70
Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?	68
Totale	1.436

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	33	0	0	0	3	1	0	2	0	0	7	0	20
2022/2023	115	9	12	7	15	6	12	1	4	47	1	1	0
2023/2024	49	3	2	8	5	4	23	0	2	0	1	0	1
2024/2025	298	10	5	3	19	7	16	16	49	58	29	40	46
2025/2026	816	32	64	41	52	75	173	95	109	83	45	25	22
2026/2027	82	8	33	20	21	0	0	0	0	0	0	0	0
Totale													1.436